AUS
NZ
UK
CA
USA
IND
_07_12_2023_11_05_52_936360.jpg)
Highlights
- Dimerix (ASX:DXB) successfully enrolls its first pediatric patient in the ACTION3 trial targeting FSGS.
- The ACTION3 trial spans 19 sites across multiple countries, with a focus on pediatric patients aged 12 to 17.
- Successful results from this trial may support the approval of DMX-200 for use in pediatric patients across major territories like the US and Europe.
Dimerix (ASX:DXB) has made a significant breakthrough in the treatment of focal segmental glomerulosclerosis (FSGS), a rare but severe kidney disease, with its first pediatric patient enrolled in the ACTION3 Phase III trial. This milestone not only represents a significant achievement in the clinical development of DMX-200, Dimerix’s leading drug candidate, but also holds considerable promise for improving treatment options for young patients suffering from this potentially life-threatening condition.
The ACTION3 trial aims to demonstrate the efficacy and safety of DMX-200 in children aged 12 to 17 years. The trial includes 19 specialist pediatric clinical sites located in four countries: Argentina, Mexico, the UK, and the US. These locations have been carefully chosen to include diverse populations while facilitating access to a broad range of pediatric patients. This wide-reaching global initiative underscores the scale and potential impact of the trial, which could offer a breakthrough in pediatric care.
FSGS is one of the leading causes of kidney failure in children, and DMX-200 presents a potentially transformative treatment option. The drug has already been granted Orphan Drug Designation in the US and Europe, and it is included in the Innovative Licensing and Access Pathway (ILAP) in the UK, emphasizing its significant potential within the therapeutic landscape for kidney diseases.
The primary goal of the ACTION3 trial is to secure regulatory approval for DMX-200's use in pediatric patients. In this rigorous, double-blind, placebo-controlled study, pediatric participants will be randomly assigned either DMX-200 or a placebo in addition to a standard angiotensin II receptor blocker. The trial design carefully monitors key indicators of kidney function, such as proteinuria, which plays a vital role in assessing the disease’s progression and the drug’s impact.
Independent monitoring has confirmed that DMX-200 remains safe for pediatric use, further strengthening the expectations for this clinical trial. Preliminary results from interim analyses of kidney function have been promising, suggesting that the drug could be a key player in reshaping the standard of care for children with FSGS.
With successful outcomes, Dimerix (ASX:DXB) could expand its approval for DMX-200 in younger populations, offering new hope for children with limited treatment options. Full patient recruitment is anticipated by the end of 2025, with data collection continuing through August 2025, marking a crucial step in bringing better treatments to vulnerable populations affected by FSGS.
